Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone Replacement for Male Opioid Agonist Maintained Patients
NCT01873989Phase 2Completed
- Sponsor
- Yale University
- Start
- Apr 2012
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of testosterone in Hypogonadism, chronic pain and opioid use disorder (OUD) (2 arms), sponsored by Yale University. Primary endpoints: Number of Participants Demonstrating Abstinence at 8 weeks, Change in Pain Ratings at 8 weeks and 1 more. Started Apr 2012; status: completed.
02
Drugs
testosterone
03
Conditions
Hypogonadismchronic painopioid use disorder (OUD)
Beyond the preview
Go deeper on NCT01873989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01873989.